UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 17, 2012
WaferGen
Bio-systems, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 333-136424 | 90-0416683 |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 7400 Paseo Padre Parkway | |
| Fremont, CA | 94555 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (510) 651-4450
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
The board of directors of WaferGen Bio-systems, Inc. (the “Company”) adopted a cash incentive program under which certain employees of the Company are eligible to receive a cash bonus, with amounts based on position and salary and ranging from 10% of an employee’s annual base salary to 50% of annual base salary, in the event of certain Company corporate transaction events such as a sale or financing. Participants in the plan include the Company’s Interim Chief Financial Officer, John Harland, who would be eligible to receive a cash bonus of up to 50% of his annual base salary, subject to the conditions of the plan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WaferGen Bio-systems, Inc. | ||
| Date: May 23, 2012 | By: | /s/ John Harland |
| John Harland | ||
| Interim Chief Financial Officer | ||